Clinical Trial AdvancementsThe initiation of the Phase 3 EMPOWHER clinical trial of zanidatamab, aimed at treating advanced breast cancer, signals progress in expanding treatment options.
Drug Development And CommercializationCompletion of rolling BLA submission for zanidatamab sets up potential US launch with significant market potential in various cancers.
Financial Growth OpportunitiesAnalysts recognize Jazz's peak revenue opportunity from indications in biliary tract cancer, gastroesophageal adenocarcinoma, and breast cancer, underpinning a strong future financial performance.